Helen Torley, President and CEO of HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO), executed a transaction involving the sale of 1,923 shares of the company's common stock on July 8, 2026. The total value of these sales reached $153,390. This disposition of shares occurred immediately following the exercise of stock options to acquire an identical number of shares.
The sales were executed through two distinct transactions. In the first instance, Torley sold 888 shares at a weighted average price of $79.276 per share, with prices fluctuating between $78.710 and $79.700. Subsequently, an additional 1,035 shares were sold at a weighted average price of $80.187 per share, with prices ranging from $79.710 to $80.490. At the time of the transaction, the stock was trading at $78.66, positioned near its 52-week high of $82.26, following a substantial 42% gain over the past year.
Earlier on the same day, Torley acquired 1,923 shares of common stock by exercising stock options at a price of $12.07 per share, totaling $23,210. These options were originally granted on February 22, 2017, and carried a ten-year term expiring in February 2027. All transactions were conducted pursuant to a pre-arranged trading plan adopted on March 21, 2025, in accordance with Rule 10b5-1.
Following these transactions, Helen Torley directly owns 767,780 shares of HALOZYME THERAPEUTICS, INC. common stock. According to InvestingPro analysis, the stock appears undervalued at current levels. An InvestingPro tip notes that management has been aggressively buying back shares, with 13 additional tips available to subscribers, along with a comprehensive Pro Research Report covering HALO and 1,400+ other US equities.
In other recent news, Halozyme Therapeutics Inc. announced the appointment of David Ramsay as President of Drug Delivery, a new role aimed at overseeing the growth of the company's drug delivery technologies. The company also disclosed the departure of its Chief Operating Officer, Cortney Caudill, effective June 30, 2026. Analysts from H.C. Wainwright reiterated a Buy rating for Halozyme, with a $95 price target, citing strong demand for ENHANZE and minimal impact from proposed CMS rules. Similarly, Benchmark maintained its Buy rating with a $90 price target, noting concerns about the long-term effects of the 2022 Inflation Reduction Act and ongoing patent litigation with Merck. Halozyme indicated it expects little to no impact on royalty revenue through at least 2035 due to the proposed Medicare Drug Price Negotiation Program rule. This outlook considers provisions that maintain orphan drug protections and address biosimilar entry. These developments highlight the company's strategic adjustments and ongoing market evaluations.